caa a22 4500 606157824 CHVBK 20210128100615.0 cr unu---uuuuu 210128e20150201xx s 000 0 eng 10.1007/s10096-014-2223-7 doi (NATIONALLICENCE)springer-10.1007/s10096-014-2223-7 Oral human papillomavirus infection in men might contribute to HPV serology [Elektronische Daten] [S. Syrjänen, T. Waterboer, K. Kero, J. Rautava, K. Syrjänen, S. Grenman, M. Pawlita] The prospective Finnish Family HPV Study evaluated the dynamics of human papillomavirus (HPV) infection within families. Here, we focused on HPV serology in men. Seroprevalence at baseline, seroconversion and decay of low-risk (LR)-HPV6 and 11, and high risk (HR)-HPV16, 18 and 45L1 antibodies in 122 men at 12, 24 and 36months were determined using Luminex-based multiplex HPV serology, and correlated with demographic data. At baseline, seropositivity to HPV6, 11, 16, 18 and 45 was observed in 41.0, 11.5, 23.0, 13.9and 5.7% of the men, respectively. In univariate analysis, LR-HPV seropositivity was related to smoking status, history of genital warts and being seropositive to HR-HPV. Oral HR-HPV DNA and baseline LR-HPV seropositivity predicted HR-HPV seropositivity. Seroconversion to HPV6, 11, 16, 18 and 45 antigens during follow-up was found in 24.6, 11.5, 5.7, 5.7and 0.8%, respectively. Seroconversion to LR-HPV was negatively related to a higher number of children and oral sex, and positively associated with seroconversion to HR-HPV. In multivariate analysis, the same predictors remained significant except for the number of children. In univariate generalised estimating equations (GEE) for HR-HPV, being seroconverted to LR-HPV was the only predictor, but lost its significance in multivariate analyses. Decay of all HPV L1 antibodies was rare and observed in 0-2%. The HPV antibody profile in men was dominated by response to HPV6, also showing the highest cumulative seroconversion. Oral HPV infection might affect HPV serology: (1) HPV DNA in oral mucosa is associated with baseline HR-HPV seropositivity and (2) practising oral sex significantly reduces longitudinal seroconversion to HPV6 and/or 11. Springer-Verlag Berlin Heidelberg, 2014 Syrjänen S. MediCity Research Laboratory and Department of Oral Pathology, Institute of Dentistry, Faculty of Medicine, University of Turku, Lemminkäisenkatu 2, 20520, Turku, Finland aut Waterboer T. Department of Genome Modifications and Carcinogenesis, Infection and Cancer Program, German Cancer Research Center (DKFZ), Heidelberg, Germany aut Kero K. Department of Obstetrics and Gynecology, Turku University Hospital, Turku, Finland aut Rautava J. MediCity Research Laboratory and Department of Oral Pathology, Institute of Dentistry, Faculty of Medicine, University of Turku, Lemminkäisenkatu 2, 20520, Turku, Finland aut Syrjänen K. Molecular Oncology Research Center, Barretos Cancer Hospital, Barretos, SP, Brazil aut Grenman S. Department of Obstetrics and Gynecology, Turku University Hospital, Turku, Finland aut Pawlita M. Department of Genome Modifications and Carcinogenesis, Infection and Cancer Program, German Cancer Research Center (DKFZ), Heidelberg, Germany aut European Journal of Clinical Microbiology & Infectious Diseases Springer Berlin Heidelberg 34/2(2015-02-01), 237-245 0934-9723 34:2<237 2015 34 10096 https://doi.org/10.1007/s10096-014-2223-7 text/html Onlinezugriff via DOI BK010053 XK010053 XK010000 Metadata rights reserved Springer special CC-BY-NC licence nationallicence 1 research-article jats NATIONALLICENCE NATIONALLICENCE NL-springer NATIONALLICENCE 856 40 https://doi.org/10.1007/s10096-014-2223-7 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Syrjänen S. MediCity Research Laboratory and Department of Oral Pathology, Institute of Dentistry, Faculty of Medicine, University of Turku, Lemminkäisenkatu 2, 20520, Turku, Finland aut NATIONALLICENCE 700 1- Waterboer T. Department of Genome Modifications and Carcinogenesis, Infection and Cancer Program, German Cancer Research Center (DKFZ), Heidelberg, Germany aut NATIONALLICENCE 700 1- Kero K. Department of Obstetrics and Gynecology, Turku University Hospital, Turku, Finland aut NATIONALLICENCE 700 1- Rautava J. MediCity Research Laboratory and Department of Oral Pathology, Institute of Dentistry, Faculty of Medicine, University of Turku, Lemminkäisenkatu 2, 20520, Turku, Finland aut NATIONALLICENCE 700 1- Syrjänen K. Molecular Oncology Research Center, Barretos Cancer Hospital, Barretos, SP, Brazil aut NATIONALLICENCE 700 1- Grenman S. Department of Obstetrics and Gynecology, Turku University Hospital, Turku, Finland aut NATIONALLICENCE 700 1- Pawlita M. Department of Genome Modifications and Carcinogenesis, Infection and Cancer Program, German Cancer Research Center (DKFZ), Heidelberg, Germany aut NATIONALLICENCE 773 0- European Journal of Clinical Microbiology & Infectious Diseases Springer Berlin Heidelberg 34/2(2015-02-01), 237-245 0934-9723 34:2<237 2015 34 10096